Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19

Abstract

Dear Editor, The World Health Organization identified a novel coronavirus in city of Wuhan in China that caused diseases of COVİD-19. The virus spread very quickly and has to date resulted in the deaths of thousands of people. Hydroxychloroquine (HCQ) has recently entered into clinical use the treatment of COVID-19 effect, both by inhibiting the viral entry into the cell and in the following stage.1 HCQ is a drug with multiple effects that has long been in use for its antimalarial and antirheumatic features.2 Previous studies have reported several dermatological side effects of HCQ, including drug eruption, pruritus, psoriasis, and alopecia.3 Psoriasis is a chronic and systemic inflammatory skin disease with multiple comorbidities that can be induced or exacerbated by several drugs, including HCQ, which is a synthetic antimalarial drug.